Pyng Medical Corp. Creates Senior Advisory Board

Market Wire, June, 2009

Pyng Medical (TSX VENTURE: PYT) announces that it has created a senior advisory board to advise its Board of Directors. The advisory board will review and advise on strategic corporate initiatives, business and competitive issues, industry trends, and potential acquisitions.

This advisory board will be lead by Pyng's director, Mr. L. J. "Bud" Evans. The initial appointees to the advisory board are LTG ® Ron Blanck MD and LTG ® Charles Roadman II MD and Mr. Brian Bristol. Their brief biographies are below:

- Dr. Blanck, D.O. is Vice Chairman & Partner of Martin, Blanck & Assoc. and Former Surgeon General of the US Army & Commander of the US Army Medical Command, Lt. General US Army (Ret.)

- Dr. Charles Harvey Roadman II, MD, CNA is Chairman of the Board of Trustee of the Altarum Institute and a Former President and CEO American Care Health Association and served as Surgeon General USAF, Lt. General USAF (Ret.)

- Mr. Bristol, M.B.A., Ph.D., was most recently Senior Managing Director and Head of Investment Banking at W. R. Hambrecht Co from 2003 to the present.

Kevin O'Neill stated on behalf of the board of directors: "We are thrilled to have Bud lead a team of advisors of such calibre and experience to help in our various strategic initiatives and in particular, penetrating new markets."

About Pyng Medical Corp.

Pyng is a leader in resuscitation innovation with simple-to-use and highly effective products including FAST1® Intraosseous Infusion System, the FASTxTM System, T-POD® Pelvic Stabilizer, and MAT® Tourniquet. The Company is awaiting FDA approval of the CRIC(TM) Cricothyrotomy System which is currently under final development. The Company plans to submit an application for FDA approval of the FASTxTM System which is currently still under development.

On behalf of the Board of Directors of Pyng Medical Corp.

Kevin O'Neill, Director, Pyng Medical Corp.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Pyng Medical Corp. Bob DiSilvio 1-800-349-7964 (x208) www.pyng.com